
## Jun Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3012429/publications.pdf Version: 2024-02-01



Ιυν Ζηγνο

#	Article	IF	CITATIONS
1	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Reports, 2022, 38, 110558.	6.4	15
2	Fighting SARS-CoV-2 with structural biology methods. Nature Methods, 2022, 19, 381-383.	19.0	3
3	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Reports, 2022, 39, 110729.	6.4	102
4	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. Signal Transduction and Targeted Therapy, 2022, 7, 139.	17.1	14
5	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	8.2	110
6	Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science, 2021, 372, 525-530.	12.6	344
7	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science, 2021, 373, 642-648.	12.6	211
8	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infectious Diseases, The, 2021, 21, 1654-1664.	9.1	200
9	CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduction and Targeted Therapy, 2021, 6, 347.	17.1	64
10	Structure of SARS-CoV-2 spike protein. Current Opinion in Virology, 2021, 50, 173-182.	5.4	122
11	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	12.6	246
12	RBD206-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern. Signal Transduction and Targeted Therapy, 2021, 6, 390.	17.1	5
13	Distinct conformational states of SARS-CoV-2 spike protein. Science, 2020, 369, 1586-1592.	12.6	995
14	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 396, 479-488.	13.7	1,011
15	HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nature Metabolism, 2020, 2, 1391-1400.	11.9	207
16	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduction and Targeted Therapy, 2020, 5, 283.	17.1	806
17	A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nature Communications, 2020, 11, 4081.	12.8	220
18	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020, 369, 650-655.	12.6	1,292